At the 2025 Radiological Society of North America (RSNA) conference, Siemens Healthineers introduces new capabilities for its Mammomat B.brilliant mammography system, advancing contrast-enhanced mammography and biopsy functionality. In addition to generating high-resolution 3D breast images via wide-angle tomosynthesis in only five seconds1, the Mammomat B.brilliant will now be equipped2 with a newly developed image reconstruction technique for contrast-enhanced examinations. This technique delivers clarity and consistency, reducing the need to switch imaging modalities and enabling faster diagnosis. Designed for cost-effectiveness and high availability, this on-site solution helps radiology practices maximize their long-term potential.
Contrast-enhanced mammography (CEM) is a highly sensitive imaging technique that is clinically indicated, for example, to clarify inconclusive findings, or to assess disease extent preoperatively. By leveraging differences in contrast uptake between healthy and malignant tissue, as well as the distinct X-ray absorption properties of iodine versus breast tissue, CEM supports radiologists in identifying and characterizing suspicious findings with greater confidence.
“Our goal was to empower clinicians with a solution that strengthens diagnostic confidence and broadens access to advanced imaging within the mammography workflow,” said Verena Schön, head of X-ray Products at Siemens Healthineers. With mammography being the most accessible breast imaging method, expanding the capabilities of existing systems is key to improving access to advanced diagnostics. “Given the anxiety associated with the clarification of potential findings detected in breast cancer screening, accelerating time-to-diagnosis is essential. It reflects our commitment to innovation in women’s healthcare and to delivering personalized care.”
The newly developed ClearCEM image reconstruction technique for the Mammomat B.brilliant2 provides crystal-clear enhancement and consistent image quality that supports lesion detection. Powered by advanced algorithms, it generates a more uniform background that supports differentiation of suspicious areas. This supports clinical decision making and may enable faster treatment initiation, while reducing the need for additional imaging or unnecessary biopsies.
If a biopsy is required following a contrast-enhanced finding, the procedure is typically performed using contrast as well, ensuring continuity in diagnostic precision. ClearCEM provides a contrast localizer image for tomosynthesis-guided biopsy, which—thanks to high depth resolution—enables targeting accuracy within ±1 mm, potentially reducing time-to-diagnosis. The combination of ClearCEM-powered scout imaging and tomosynthesis-based targeting within the same compression is designed to strengthen confidence and eases the biopsy procedure. The streamlined process can add to increased system availability, which is a key advantage in high-volume clinical settings.
Dianne Georgian-Smith, MD, a radiologist at Envision Healthcare, Nashville, Tenn., says regarding the new imaging technique in clinical testing: “The image quality with ClearCEM is exceptional, even in dense breast tissue. ClearCEM provides a remarkably uniform background, which significantly improves the visibility of enhancing lesions.”3
Further information on the Mammomat B.brilliant can be found here.
Media contact
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
